The US National Institute of Allergy and Infectious Diseases and Foundation for the National Institutes of Health convened a 2-day workshop announcing four agents to enter RECOVER–Treating Long COVID clinical trials and obtained input on future directions.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout

References
Hou, Y. et al. Open Forum Infect. Dis. 12, ofaf533 (2025).
CDC. Long COVID basics https://www.cdc.gov/long-covid/about/index.html (2025).
Funk, A. L. et al. JAMA Netw. Open 5, e2223253 (2022).
Lopez-Leon, S. et al. Sci. Rep. 12, 9950 (2022).
Pellegrino, R., Chiappini, E., Licari, A., Galli, L. & Marseglia, G. L. Eur. J. Pediatr. 181, 3995–4009 (2022).
Gross, R. S. et al. JAMA 332, 1174–1188 (2024).
Bombardieri, A. M. & Denoue, C. F. Reg. Anesth. Pain. Med. https://doi.org/10.1136/rapm-2025-106879 (2025).
Duricka, D. & Liu, L. Auton. Neurosci. 254, 103195 (2024).
Metz, T. D. et al. Obstet. Gynecol. 144, 411–420 (2024).
Jaswa, E. G. et al. JAMA Netw. Open 7, e2439792 (2024).
Vrantsidis, D. M. et al. JAMA Netw. Open 7, e2443697 (2024).
Swank, Z. et al. Clin. Microbiol. Infect. 30, 1599–1605 (2024).
Acknowledgements
The coauthors acknowledge the RECOVER-TLC workshop organizing committee: S. J. Adam (FNIH); L. R. Baden (Brigham and Women’s Hospital, Harvard University); J. Burns (Boston Children’s Hospital, Harvard University); H. Davis (Patient-Led Research Collaborative); S. E. Dunsmore (US National Center for Advancing Translational Sciences); L. J. Fine (US National Heart, Lung, and Blood Institute (NHLBI)); R. S. Gross (New York University); L. Gutmann (Indiana University); S. L. Hodder (West Virigina University); L. Jones (MEAction); J. A. Krishnan (University of Illinois Chicago); E. F. Lewis (Stanford University); C.-K. Liang (NIAID); J. P. Menetski (FNIH); S. Mohandas (Children’s Hospital Los Angeles); M. Pennini (FNIH); J. H. Powers III (NIAID); S. W. Read (NIAID); Y. D. Rosenberg (NHLBI); E. Roy (FNIH); U. Singh (University of Iowa); S. S. Spudich (Yale University); M. S. Stockwell (Columbia University); L. Tannenbaum (Open Medicine Foundation); K. M. Tomashek (NIAID); C. B. Wright (US National Institute of Neurological Disorders and Stroke); and A. B. Yonts (Children’s National Hospital).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Eisinger, R.W., Breen, J.J., Beigel, J. et al. Progress on the pathway to long COVID treatments. Nat Immunol 26, 2126–2129 (2025). https://doi.org/10.1038/s41590-025-02336-y
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41590-025-02336-y